Comments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare ...
Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results